Skip to main content
Fig. 4 | Breast Cancer Research

Fig. 4

From: Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer

Fig. 4

Myeloid immune cell subsets differ significantly between the different versions of the MMTV-PyMT breast tumor model. Tumors from the autochthonous MMTV-PyMT model were harvested and single-cell suspensions were generated. Cells (1E6, 1E5, or 1E4) were injected into the mammary fat pad of FVB/NJ wild-type mice. When tumors reached 100 mm3, tumors were obtained and processed into a single-cell suspension for immunophenotyping by flow cytometry. ad Analysis of cells subsets as a percent of myeloid cells (CD11b+) include a myeloid-derived suppressor cells (MDSC (GR1+)), b PD-L1+F4/80+, c PD-L1 F4/80+, and d other CD11b+ populations; e Analysis of the myeloid cells subsets as a percent of viable cells include f analysis of PD-L1 expression on myeloid cells (CD11b+) and g cancer cells represented by CD45-. h Analysis of the ratio of lymphocytes expressing PD-1. i Analysis of M1-like macrophage markers, CD40+, CD80+, and CD86+ and an M2-like macrophage marker, CD206+, as a ratio of total myeloid cells (CD11b+, top), and mature macrophages (F4/80+, bottom). Graphs show mean ± SEM from at least two independent experiments with at least three mice per group. Each data point represents an individual mouse. Unpaired two-tailed t test. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.001

Back to article page